Therefore, the FDA approved ICIs that block the interaction between CTLA-4 and its ligand or block the interaction between PD-1 and PD-L1, thereby restoring cytotoxic T cell immune response in recognizing and destroying cancer cells thus preventing growth of tumors (9, 10). Here, CTLA4 is linked to cancer.